{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:38:05Z","timestamp":1790969885324,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":35,"publisher":"Springer US","isbn-type":[{"value":"9781071622643","type":"print"},{"value":"9781071622650","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2265-0_9","type":"book-chapter","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T16:04:57Z","timestamp":1650297897000},"page":"181-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantitative Systems Toxicology and Drug Development: The DILIsym Experience"],"prefix":"10.1007","author":[{"given":"Paul B.","family":"Watkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"issue":"1","key":"9_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bjornsson ES et al (2019) Drug-induced liver injury. Nat Rev Dis Primers 5(1):58\u201372","journal-title":"Nat Rev Dis Primers"},{"key":"9_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.apha.2019.02.004","volume":"85","author":"PB Watkins","year":"2019","unstructured":"Watkins PB (2019) Idiosyncratic drug-induced liver injury in patients: detection, severity assessment, and regulatory implications. Adv Pharmacol 85:165\u2013193","journal-title":"Adv Pharmacol"},{"issue":"2","key":"9_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/cts.12900","volume":"14","author":"RJ Church","year":"2021","unstructured":"Church RJ, Watkins P (2021) The challenge of interpreting alanine aminotransferase elevations in clinical trials of new drug candidates. Clin Transl Sci 14(2):434\u2013436","journal-title":"Clin Transl Sci"},{"issue":"4","key":"9_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cpt.564","volume":"101","author":"M Mosedale","year":"2017","unstructured":"Mosedale M, Watkins PB (2017) Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Invited \u201cstate-of-the-art\u201d review. Clin Pharmacol Ther 101(4):469\u2013480","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/toxsci\/kfx284","volume":"162","author":"R Chan","year":"2018","unstructured":"Chan R, Benet LZ (2018) Measures of BSEP inhibition in vitro are not useful predictors of DILI. Toxicol Sci 162(2):499\u2013508","journal-title":"Toxicol Sci"},{"issue":"6","key":"9_CR6","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.3390\/ijms22062954","volume":"22","author":"A Jee","year":"2021","unstructured":"Jee A, Sernoskie SC, Uetrecht J (2021) Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci 22(6):2954","journal-title":"Int J Mol Sci"},{"issue":"Supplement C","key":"9_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ddmod.2017.04.001","volume":"22","author":"BA Howell","year":"2016","unstructured":"Howell BA, Siler SQ, Barton HA et al (2016) Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development. Drug Discov Today Dis Model 22(Supplement C):5\u201313","journal-title":"Drug Discov Today Dis Model"},{"issue":"1","key":"9_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/bdd.1878","volume":"35","author":"LKM Shoda","year":"2014","unstructured":"Shoda LKM, Woodhead JL, Siler SQ et al (2014) Linking physiology to toxicity using DILIsym\u00ae, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos 35(1):33\u201349","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"9_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cld.2019.09.003","volume":"24","author":"PB Watkins","year":"2020","unstructured":"Watkins PB (2020) Quantitative systems toxicology approaches to understand and predict drug-induced liver injury. Clin Liver Dis 24(1):49\u201360","journal-title":"Clin Liver Dis"},{"issue":"2","key":"9_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/cts.12629","volume":"12","author":"PB Watkins","year":"2019","unstructured":"Watkins PB (2019) The DILI-Sim initiative: insights into hepatotoxicity mechanisms and biomarker interpretation. Clin Transl Sci 12(2):122\u2013129","journal-title":"Clin Transl Sci"},{"key":"9_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fphar.2014.00240","volume":"5","author":"JL Woodhead","year":"2014","unstructured":"Woodhead JL, Yang K, Siler SQ et al (2014) Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol 5:240","journal-title":"Front Pharmacol"},{"issue":"6","key":"9_CR12","doi-asserted-by":"publisher","first-page":"e00523","DOI":"10.1002\/prp2.523","volume":"7","author":"G Generaux","year":"2019","unstructured":"Generaux G, Lakhani VV, Yang Y et al (2019) Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity. Pharmacol Res Perspect 7(6):e00523","journal-title":"Pharmacol Res Perspect"},{"key":"9_CR13","doi-asserted-by":"publisher","first-page":"23.7.1","DOI":"10.1002\/0471140856.tx2307s61","volume":"61","author":"JG Kenna","year":"2014","unstructured":"Kenna JG (2014) Current concepts in drug-induced bile salt export pump (BSEP) interference. Curr Protoc Toxicol 61:23.7.1\u201323.715","journal-title":"Curr Protoc Toxicol"},{"issue":"1","key":"9_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/toxsci\/kfy191","volume":"166","author":"C Battista","year":"2018","unstructured":"Battista C, Yang K, Stahl SH et al (2018) Using quantitative systems toxicology to investigate observed species differences in CKA-mediated hepatotoxicity. Toxicol Sci 166(1):123\u2013130","journal-title":"Toxicol Sci"},{"issue":"11","key":"9_CR15","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1007\/s00204-017-1994-x","volume":"91","author":"F Paech","year":"2017","unstructured":"Paech F, Messner S, Spickermann J et al (2017) Mechanisms of hepatotoxicity associated with the monocyclic beta-lactam antibiotic BAL30072. Arch Toxicol 91(11):3647\u20133662","journal-title":"Arch Toxicol"},{"issue":"2","key":"9_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/toxsci\/kfaa019","volume":"175","author":"DM Longo","year":"2020","unstructured":"Longo DM, Shoda LKM, Howell BA et al (2020) Assessing effects of BHV-0223 40 mg Zydis sublingual formulation and Riluzole 50 mg Oral tablet on liver function test parameters utilizing DILIsym. Toxicol Sci 175(2):292\u2013300","journal-title":"Toxicol Sci"},{"issue":"5","key":"9_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/clpt.2014.158","volume":"96","author":"K Yang","year":"2014","unstructured":"Yang K, Woodhead JL, Watkins PB et al (2014) Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 96(5):589\u2013598","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/psp4.12053","volume":"5","author":"DM Longo","year":"2016","unstructured":"Longo DM, Yang Y, Watkins PB et al (2016) Elucidating differences in the hepatotoxic potential of Tolcapone and Entacapone with DILIsym\u00ae, a mechanistic model of drug-induced liver injury. CPT Pharmacometrics Syst Pharmacol 5(1):31\u201339","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"9_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"P Watkins","year":"2015","unstructured":"Watkins P, Lewis J, Kaplowitz N et al (2015) Clinical pattern of Tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 38(11):1103\u20131113","journal-title":"Drug Saf"},{"issue":"8","key":"9_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1124\/dmd.119.086785","volume":"47","author":"J Bezencon","year":"2019","unstructured":"Bezencon J, Beaudoin JJ, Ito K et al (2019) Altered expression and function of hepatic transporters in a rodent model of polycystic kidney disease. Drug Metab Dispos 47(8):899\u2013906","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"9_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/cpt.2007","volume":"109","author":"JJ Beaudoin","year":"2021","unstructured":"Beaudoin JJ, Brock WJ, Watkins PB, Brouwer KLR (2021) Quantitative systems toxicology modeling predicts that reduced biliary efflux contributes to Tolvaptan hepatotoxicity. Clin Pharmacol Ther 109(2):433\u2013442","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/dmd.118.083907","volume":"47","author":"JJ Beaudoin","year":"2019","unstructured":"Beaudoin JJ, Bezencon J, Cao Y et al (2019) Altered hepatobiliary disposition of Tolvaptan and selected Tolvaptan metabolites in a rodent model of polycystic kidney disease. Drug Metab Dispos 47(2):155\u2013163","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"9_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","volume":"155","author":"JL Woodhead","year":"2017","unstructured":"Woodhead JL, Brock WJ, Roth SE et al (2017) Application of a mechanistic model to evaluate putative mechanisms of Tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci 155(1):61\u201374","journal-title":"Toxicol Sci"},{"issue":"2","key":"9_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.74","volume":"3","author":"BA Howell","year":"2014","unstructured":"Howell BA, Siler SQ, Shoda LKM et al (2014) A mechanistic model of drug-induced liver injury aids the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacometrics Syst Pharmacol 3(2):e98","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"9_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/cpt.711","volume":"102","author":"DM Longo","year":"2017","unstructured":"Longo DM, Generaux GT, Howell BA et al (2017) Refining liver safety risk assessment: application of mechanistic modeling and serum biomarkers to Cimaglermin alfa (GGF2) clinical trials. Clin Pharmacol Ther 102(6):961\u2013969","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/1535370217740853","volume":"243","author":"RJ Church","year":"2018","unstructured":"Church RJ, Watkins PB (2018) In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials. Exp Biol Med (Maywood) 243(3):300\u2013307","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"9_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/cpt.619","volume":"101","author":"K Yang","year":"2017","unstructured":"Yang K, Battista C, Woodhead JL et al (2017) Systems pharmacology modeling of drug-induced hyperbilirubinemia: differentiating hepatotoxicity and inhibition of enzymes\/transporters. Clin Pharmacol Ther 101(4):501\u2013509","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11095-019-2726-0","volume":"37","author":"JL Woodhead","year":"2020","unstructured":"Woodhead JL, Pellegrini L, Shoda LKM, Howell BA (2020) Comparison of the hepatotoxic potential of two treatments for autosomal-dominant polycystic kidney disease using quantitative systems toxicology modeling. Pharm Res 37(2):24","journal-title":"Pharm Res"},{"issue":"14","key":"9_CR29","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/0333102419869918","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Tepper SJ, Watkins PB et al (2019) Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia 39(14):1753\u20131761","journal-title":"Cephalalgia"},{"issue":"2","key":"9_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1124\/jpet.112.192930","volume":"342","author":"JL Woodhead","year":"2012","unstructured":"Woodhead JL, Howell BA, Yang Y et al (2012) An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 342(2):529\u2013540","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104788","volume":"118","author":"G Eichenbaum","year":"2020","unstructured":"Eichenbaum G, Yang K, Gebremichael Y et al (2020) Application of the DILIsym(R) quantitative systems toxicology drug-induced liver injury model to evaluate the carcinogenic hazard potential of acetaminophen. Regul Toxicol Pharmacol 118:104788","journal-title":"Regul Toxicol Pharmacol"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"117762501769607","DOI":"10.1177\/1177625017696074","volume":"11","author":"LK Shoda","year":"2017","unstructured":"Shoda LK, Battista C, Siler SQ et al (2017) Mechanistic modelling of drug-induced liver injury: investigating the role of innate immune responses. Gene Regul Syst Bio 11:1177625017696074","journal-title":"Gene Regul Syst Bio"},{"issue":"6","key":"9_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI (2018) Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 38(6):976\u2013987","journal-title":"Liver Int"},{"issue":"2","key":"9_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/toxsci\/kfy253","volume":"167","author":"DM Longo","year":"2019","unstructured":"Longo DM, Woodhead JL, Walker P et al (2019) Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury. Toxicol Sci 167(2):458\u2013467","journal-title":"Toxicol Sci"},{"issue":"3","key":"9_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1039\/c8tx00016f","volume":"7","author":"R Chan","year":"2018","unstructured":"Chan R, Benet LZ (2018) Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of in vitro methodologies vs BDDCS classification. Toxicol Res (Camb) 7(3):358\u2013370","journal-title":"Toxicol Res (Camb)"}],"container-title":["Methods in Molecular Biology","Systems Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2265-0_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T16:12:22Z","timestamp":1650384742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2265-0_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071622643","9781071622650"],"references-count":35,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2265-0_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"19 April 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}